Status
Conditions
Treatments
About
To analyze the effects of altering the time of ingestion of participants' habitual medication (i.e., metformin, statins, ARAII/IACE) and meals around the time of exercise training (exercise fasted or fed) on the improvement of metabolic syndrome factors (hypertension, insulin sensitivity, dyslipidemia, and obesity). There will be a preliminary study of the effects of training "time-of-day" on the primary study outcomes.
Full description
Objective: The purpose is to study in a group of adults with metabolic syndrome and obesity, the effects of altering timing between exercise training, meals, and their habitual medication on the improvement in the factors that compose the metabolic syndrome (i.e., hypertension, insulin resistance, central obesity, and dyslipidemia). The main objective is to find the most productive combination between exercise training and the timing of their habitual pharmacological treatment, and meal ingestion for lowering those factors.
Methods and design: Cross-over randomized double-blinded, pretest-posttest control group experimental design. The project will be developed in a single center with the collaboration of the regional public health system (SECAM). There will be a preliminary study of the effects of training "time-of-day" on three parallel groups of individuals.
Subjects: Will be referred by their primary care physicians to our study unit or recruited by advertisements in local media.
Up to 180 subjects, all of them with metabolic syndrome will be recruited (>25% women).
Measurements:
Specifically, we will study if the cardiovascular and metabolic adaptations to aerobic training that result in amelioration of metabolic syndrome factors are potentiated by correct timming of training, meals, and medicine around exercise training time.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Cardiovascular disease or musculo-skeletal that prevents them from being able to perform intense exercise.
Primary purpose
Allocation
Interventional model
Masking
160 participants in 3 patient groups
Loading...
Central trial contact
Ricardo Mora-Rodriguez, PhD; Juan F Ortega, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal